{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T12:24:47Z","timestamp":1783513487502,"version":"3.55.0"},"reference-count":29,"publisher":"Bioscientifica","issue":"2","content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2005,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Long-term secretion of insulin by host muscle following transduction with an insulin gene construct offers the potential of gene therapy for diabetes without immunosuppression. Clinical implementation will be dependent on proof of principle in human tissue and a system for safely regulating basal insulin levels. Liposomal co-transfection with a tetracycline-responsive wild type human preproinsulin (pTRE-hppI1) or mutant construct (pTRE-hppI4), in which PC2 and PC3 cleavage sites were altered to form tetrabasic consensus sites for furin, together with pTet-off (coding for a transactivating protein) was evaluated in the C2C12 mouse myoblast cell line and human myoblasts following establishment in primary culture. In the absence of tetracycline, (pro)insulin secretion in C2C12 and human myoblasts transfected with tetracycline-responsive hppI1 and hppI4 constructs was comparable to that following transfection with equivalent constructs under the control of a constitutively active cytomegaloviral promoter. Percentage processing to mature insulin was &amp;lt;5% in C2C12 and human myoblasts transfected with pTet-off\/pTRE-hppI1 but &amp;gt;90% in C2C12 cells and 45\u201360% in human myoblasts on transfection with pTet-off\/pTRE-hppI4. Incremental dose-responsive suppression of proinsulin secretion was demonstrated in C2C12 and human myoblasts expressing pTet-off\/pTRE-hppI1 following incubation with tetracycline (0\u2013100 \u03bcg\/ml) for up to 72 h. Reversibility was confirmed following tetracycline withdrawal. Dose-responsive tetracycline-inducible repression of mature insulin secretion was confirmed in C2C12 cells following transfection with pTet-off\/pTRE-hppI4. Regulation of human proinsulin biosynthesis and secretion has been attained in vivo following plasmid-mediated gene transfer to rat skeletal muscle and oral tetracycline administration. In conclusion, processing to mature insulin has been confirmed following plasmid-mediated gene transfer to human muscle in addition to in vitro- and in vivo-regulated human proinsulin secretion employing the safe and well-tolerated antibiotic, tetracycline.<\/jats:p>","DOI":"10.1677\/jme.1.01646","type":"journal-article","created":{"date-parts":[[2005,4,8]],"date-time":"2005-04-08T13:13:01Z","timestamp":1112965981000},"page":"391-403","update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-6","source":"Crossref","is-referenced-by-count":12,"title":["Tetracycline-regulated secretion of human (pro)insulin following plasmid-mediated transfection of human muscle"],"prefix":"10.1530","volume":"34","author":[{"given":"Magdalene O","family":"Wilson","sequence":"first","affiliation":[{"name":"Diabetes Research Group, School of Clinical Medical Sciences, University of Newcastle upon Tyne, Framlington Place, Newcastle upon Tyne NE2 4HH, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen T","family":"Scougall","sequence":"additional","affiliation":[{"name":"Diabetes Research Group, School of Clinical Medical Sciences, University of Newcastle upon Tyne, Framlington Place, Newcastle upon Tyne NE2 4HH, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jarupa","family":"Ratanamart","sequence":"additional","affiliation":[{"name":"Diabetes Research Group, School of Clinical Medical Sciences, University of Newcastle upon Tyne, Framlington Place, Newcastle upon Tyne NE2 4HH, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A","family":"McIntyre","sequence":"additional","affiliation":[{"name":"Diabetes Research Group, School of Clinical Medical Sciences, University of Newcastle upon Tyne, Framlington Place, Newcastle upon Tyne NE2 4HH, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A M","family":"Shaw","sequence":"additional","affiliation":[{"name":"Diabetes Research Group, School of Clinical Medical Sciences, University of Newcastle upon Tyne, Framlington Place, Newcastle upon Tyne NE2 4HH, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","reference":[{"key":"2026070808070735400_ABAI-ETAL-1999","doi-asserted-by":"crossref","unstructured":"Abai\n            AM\n          , Hobart PM & Barnhart KM 1999 Insulin delivery with plasmid DNA. Human Gene Therapy102637\u20132649.","DOI":"10.1089\/10430349950016672"},{"key":"2026070808070735400_BELLES-ISLES-ETAL-1993","unstructured":"Belles-Isles\n            M\n          , Roy R, Dansereau G, Goulet M, Roy B, Bouchard JP & Tremblay JP 1993 Rapid selection of donor myoblast clones for muscular dystrophy therapy using cell surface expression of NCAM. European Journal of Histochemistry37375\u2013380."},{"key":"2026070808070735400_BLAU-AND-WEBSTER-1981","unstructured":"Blau\n            HM\n           & Webster C 1981 Isolation and characterization of human muscle cells. PNAS785623\u20135627."},{"key":"2026070808070735400_CROZE-AND-PRUDHOMME-2003","unstructured":"Croze\n            F\n           & Prud\u2019homme GJ 2003 Gene therapy of streptozotocin-induced diabetes by intramuscular delivery of modified preproinsulin genes Journal of Gene Medicine5425\u2013437."},{"key":"2026070808070735400_DIABETES-CONTROL-AND-COMPLICATIONS-TRIAL-RESEARCH-GROUP-1993","unstructured":"Diabetes Control and Complications Trial Research Group 1993 The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New England Journal of Medicine329977\u2013986."},{"key":"2026070808070735400_FIORINA-ETAL-2001","doi-asserted-by":"crossref","unstructured":"Fiorina\n            P\n          , La Rocca E, Venturini M, Minicucci F, Fermo I, Paroni R, Angelo A Sblendido M, Carlo VD, Cristallo M, Maschio AD, Pozza G & Secchi A 2001 Effects of kidney-pancreas transplantation on atherosclerotic risk factors and endothelial function in patients with uremia and Type 1 diabetes. Diabetes50496\u2013501.","DOI":"10.2337\/diabetes.50.3.496"},{"key":"2026070808070735400_GENE-THERAPY-CLINICAL-TRIALS","unstructured":"Gene Therapy Clinical Trials online database (www.wiley.co.uk.\/genetherapy) accessed 23.04.04."},{"key":"2026070808070735400_HALSE-ETAL-1999","doi-asserted-by":"crossref","unstructured":"Halse\n            R\n          , Rochford JJ, McCormack JG, Vandenheede JR, Hemmings BA & Yeaman SJ 1999 Control of glycogen synthesis in cultured human muscle cells. Journal of Biological Chemistry274776\u2013780.","DOI":"10.1074\/jbc.274.2.776"},{"key":"2026070808070735400_HARTIKKA-ETAL-1996","doi-asserted-by":"crossref","unstructured":"Hartikka\n            J\n          , Sawdey M, Cornefert-Jensen F, Margalith M, Barnhart K, Nolasco M, Vahlsing HL, Meek J, Marquet M, Hobart P, Norman J & Manthorpe M 1996 An improved plasmid DNA expression vector for direct injection into skeletal muscle. Human Gene Therapy71205\u20131217.","DOI":"10.1089\/hum.1996.7.10-1205"},{"key":"2026070808070735400_HAY-AND-DOCHERTY-2003","doi-asserted-by":"crossref","unstructured":"Hay\n            CW\n           & Docherty K 2003 Enhanced expression of a furin-cleavable proinsulin. Journal of Molecular Endocrinology31597\u2013607.","DOI":"10.1677\/jme.0.0310597"},{"key":"2026070808070735400_HORTON-ETAL-1999","unstructured":"Horton\n            HM\n          , Anderson D, Hernandez P & Barnhart KM 1999 A gene therapy for cancer using intramuscular injection of plasmid DNA encoding interferon alpha. PNAS961553\u20131558."},{"key":"2026070808070735400_KAWAKAMI-ETAL-1992","doi-asserted-by":"crossref","unstructured":"Kawakami\n            Y\n          , Yamaoka T, Hirochika R, Yamashita K, Itakura M & Nakauchi H 1992 Somatic gene therapy for diabetes with an immunological safety system for complete removal of transplanted cells. Diabetes41956\u2013961.","DOI":"10.2337\/diab.41.8.956"},{"key":"2026070808070735400_KLEINMAN-ETAL-1982","doi-asserted-by":"crossref","unstructured":"Kleinman\n            HK\n          , McGarvey ML, Liotta LA, Robey PG, Trygvasson K & Martin GR 1982 Isolation and characterization of type IV procollagen, laminin and heparan sulfate proteoglycan from the EHS sacroma. Biochemistry246188\u20136193.","DOI":"10.1021\/bi00267a025"},{"key":"2026070808070735400_KON-ETAL-1999","doi-asserted-by":"crossref","unstructured":"Kon\n            OL\n          , Sivakumar S, Teoh KL, Lok SH & Long YC 1999 Naked plasmid-mediated gene transfer to skeletal muscle ameliorates diabetes mellitus. Journal of Gene Medicine1186\u2013194.","DOI":"10.1002\/(SICI)1521-2254(199905\/06)1:3<186::AID-JGM33>3.0.CO;2-W"},{"key":"2026070808070735400_MARTINENGHI-ETAL-2002","doi-asserted-by":"crossref","unstructured":"Martinenghi\n            S\n          , Cusella De Angelis G, Biressi S, Amadio S, Bifari F, Roncarolo MG, Bordignon C & Falqui L 2002 Human insulin production and amelioration of diabetes in mice by electrotransfer-enhanced plasmid DNA gene transfer to the skeletal muscle. Gene Therapy91429\u20131437.","DOI":"10.1038\/sj.gt.3301804"},{"key":"2026070808070735400_OWENS-ETAL-2001","doi-asserted-by":"crossref","unstructured":"Owens\n            DR\n          , Zinman B & Bolli GB 2001 Insulins today and beyond. Lancet358739\u2013746.","DOI":"10.1016\/S0140-6736(01)05842-1"},{"key":"2026070808070735400_REES-ETAL-1996","doi-asserted-by":"crossref","unstructured":"Rees\n            S\n          , Coote J, Stables J, Goodson S, Harris S & Lee MG 1996 Bicistronic vector for the creation of stable mammalian cell lines that predisposes all antibiotics-resistant cells to express recombinant protein. BioTechniques20102\u2013110.","DOI":"10.2144\/96201st05"},{"key":"2026070808070735400_RIDDLE-ETAL-2003","unstructured":"Riddle\n            MC\n          , Rosenstock J & Gerich J 2003 The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care263080\u20133086."},{"key":"2026070808070735400_RIVERA-ETAL-2000","doi-asserted-by":"crossref","unstructured":"Rivera\n            VM\n          , Wang X, Wardwell S, Courage NL, Volchuk A, Keenan T, Holt DA, Gilman M, Orci L, Cerasoli F Jr, Rothman JE & Clackson T 2000 Regulation of protein secretion through controlled aggregation in the endoplasmic reticulum. Science287826\u2013830.","DOI":"10.1126\/science.287.5454.826"},{"key":"2026070808070735400_RYAN-ETAL-2002","unstructured":"Ryan\n            EA\n          , Lakey JRT & Paty BW 2002 Successful islet transplantation: continued insulin reserve provides long-term glycemic control. Diabetes512148\u20132157."},{"key":"2026070808070735400_SCOUGALL-AND-SHAW-2003","doi-asserted-by":"crossref","unstructured":"Scougall\n            KT\n           & Shaw JAM 2003 Tetracycline-regulated secretion of human insulin in transfected primary myoblasts. Biochemical and Biophysical Research Communications304167\u2013175.","DOI":"10.1016\/S0006-291X(03)00553-9"},{"key":"2026070808070735400_SCOUGALL-ETAL-2003","doi-asserted-by":"crossref","unstructured":"Scougall\n            KT\n          , Maltin CA & Shaw JM 2003 Tetracycline-regulated secretion of human insulin in transfected non-endocrine cell line. Journal of Molecular Endocrinology30331\u2013346.","DOI":"10.1677\/jme.0.0300331"},{"key":"2026070808070735400_SHAW-AND-DOCHERTY-2002","unstructured":"Shaw\n            JAM\n           & Docherty K 2002 Genetic engineering in the treatment of diabetes. In Oxford Textbook of Endocrinology and Diabetes, pp 1866\u20131872. Eds J Wass & S Shalet. Oxford, UK: Oxford University Press."},{"key":"2026070808070735400_SHAW-ETAL-2002","doi-asserted-by":"crossref","unstructured":"Shaw\n            JAM\n          , Delday MI, Hart AW & Docherty K 2002 Secretion of bioactive human insulin following plasmid-mediated gene transfer to non-neuroendocrine cell lines, primary cultures, and rat skeletal muscle in vivo.Journal of Endocrinology72653\u2013672.","DOI":"10.1677\/joe.0.1720653"},{"key":"2026070808070735400_SIMONSON-ETAL-1996","doi-asserted-by":"crossref","unstructured":"Simonson\n            GD\n          , Groskreutz DJ, Gorman CM & MacDonald MJ 1996 Synthesis and processing of genetically modified human proinsulin by rat myoblast primary cultures. Human Gene Therapy771\u201378.","DOI":"10.1089\/hum.1996.7.1-71"},{"key":"2026070808070735400_TRIPATHY-ETAL-1996","doi-asserted-by":"crossref","unstructured":"Tripathy\n            SK\n          , Svensson EC, Black HB, Goldwasser E, Margalith M., Hobart PM & Leiden JM 1996 Long-term expression of erythropoietin in the systemic circulation of mice after intramuscular injection of a plasmid DNA vector. PNAS9310876\u201310880.","DOI":"10.1073\/pnas.93.20.10876"},{"key":"2026070808070735400_UK-PROSPECTIVE-DIABETES-STUDY-GROUP-1998","unstructured":"UK Prospective Diabetes Study Group 1998 Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes. Lancet352837\u2013853."},{"key":"2026070808070735400_WOLFF-ETAL-1992","doi-asserted-by":"crossref","unstructured":"Wolff\n            JA\n          , Ludtke JJ, Acsadi G, Williams P & Jani A 1992 Long-term persistence of plasmid DNA and foreign gene expression in mouse muscle. Human Molecular Genetics1363\u2013369.","DOI":"10.1093\/hmg\/1.6.363"},{"key":"2026070808070735400_YAMASAKI-ETAL-1999","doi-asserted-by":"crossref","unstructured":"Yamasaki\n            K\n          , Takashi S, Nemoto M, Eto Y & Tajima N 1999 Differentiation-induced insulin secretion from nonendocrine cells with engineered human proinsulin cDNA. Biochemical and Biophysical Research Communications265361\u2013365.","DOI":"10.1006\/bbrc.1999.1698"}],"container-title":["Journal of Molecular Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jme.bioscientifica.com\/view\/journals\/jme\/34\/2\/0340391.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.bioscientifica.com\/jme\/article-pdf\/34\/2\/391\/48559\/0340391.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/jme\/article-pdf\/34\/2\/391\/48559\/0340391.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T12:07:17Z","timestamp":1783512437000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/jme\/article\/34\/2\/391\/6662\/Tetracycline-regulated-secretion-of-human-pro"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,4,1]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2005,4,1]]}},"URL":"https:\/\/doi.org\/10.1677\/jme.1.01646","relation":{},"ISSN":["1479-6813","0952-5041"],"issn-type":[{"value":"1479-6813","type":"electronic"},{"value":"0952-5041","type":"print"}],"subject":[],"published":{"date-parts":[[2005,4,1]]}}}